Counterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patients

Author： Chapman Paul B.  

Publisher： Cambridge Scholars Publishing in association with GSE Research

ISSN： 1540-1405

Source： Journal of the National Comprehensive Cancer Network (JNCCN), Vol.2, Iss.1, 2004-01, pp. : 69-72

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

By Sabel Michael S.   Sondak Vernon K.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 1, 2004-01 ,pp. : 61-68

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Is There a Role for Adjuvant High-Dose Interferon- -2b in the Management of Melanoma?

By Sabel M.S.   Sondak V.K.  

Drugs, Vol. 63, Iss. 11, 2003-01 ,pp. : 1053-1058

Adis International

Access to resources Recommend Favorite

Interferon-α-2b: Primary cutaneous malignant melanoma (first report) in patients with malignant melanoma: 3 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1260, 2009-01 ,pp. : 20-21

Adis International

Access to resources Recommend Favorite

Cost-effectiveness of interferon-α2 as adjuvant therapy in malignant melanoma

By Lafuma Antoine   Grob Jean Jacques  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 3, 2003-03 ,pp. : 343-349

Informa Healthcare

Access to resources Recommend Favorite

Interferon-α of variable value in melanoma

By  

Inpharma, Vol. 1, Iss. 1599, 2007-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite